1. [P1–066]: ASSESSMENT OF AZELIRAGON QTC LIABILITY THROUGH INTEGRATED, MODEL‐BASED CONCENTRATION QTC ANALYSIS. (1st July 2017) Authors: Burstein, Aaron H.; Brantley, Scott J.; Dunn, Imogene; Altstiel, Larry D.; Schmith, Virginia Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 5 Page Start: P262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. [P2–025]: EFFECT OF FOOD ON THE PHARMACOKINETICS OF AZELIRAGON IN HEALTHY ADULT SUBJECTS. (1st July 2017) Authors: Burstein, Aaron H.; Dunn, Imogene; Bush, Mark A.; Altstiel, Larry D. Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 12 Page Start: P613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Assessment of Azeliragon QTc Liability Through Integrated, Model‐Based Concentration QTc Analysis. Issue 4 (1st April 2019) Authors: Burstein, Aaron H.; Brantley, Scott J.; Dunn, Imogene; Altstiel, Larry D.; Schmith, Virginia Journal: Clinical pharmacology in drug development Issue: Volume 8:Issue 4(2019) Page Start: 426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effects of azeliragon on ADAS‐cog and CDR domains and individual items in patients with mild Alzheimer's disease and type 2 diabetes (T2D): Human/Human trials: Other. (7th December 2020) Authors: Burstein, Aaron H.; Dunn, Imogene; Gooch, Ann M.; Valcarce, Carmen Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy. Issue 3 (10th May 2017) Authors: Landen, Jaren W.; Cohen, Sharon; Billing, Clare B.; Cronenberger, Carol; Styren, Scot; Burstein, Aaron H.; Sattler, Catherine; Lee, Jae‐Hong; Jack, Clifford R.; Kantarci, Kejal; Schwartz, Pamela F.; Duggan, William T.; Zhao, Qinying; Sprenger, Ken; Bednar, Martin M.; Binneman, Brendon Journal: Alzheimer's & dementia Issue: Volume 3:Issue 3(2017) Page Start: 339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. O4‐08‐05: Azeliragon Phase 2B Survival Analysis Supports Beneficial Effects on Delaying Time to Cognitive Deterioration in Patients with Mild Alzheimer's Disease. (1st July 2016) Authors: Burstein, Aaron H.; Dunn, Imogene; Soeder, Tom; Sabbagh, Marwan N.; Altstiel, Larry D. Journal: Alzheimer's & dementia Issue: Volume 12:Supplement 7S(2016)Part 7 Page Start: P352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. O4‐11‐04: LINKING DIABETES AND ALZHEIMER'S DISEASE THROUGH RAGE: A RETROSPECTIVE ANALYSIS OF AZELIRAGON PHASE 2 AND PHASE 3 STUDIES. (1st July 2019) Authors: Valcarce, Carmen; Dunn, Imogene; Burstein, Aaron H. Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7S(2019)Part 24 Page Start: P1263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗